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Abstract
Bone morphogenetic proteins (BMPs) are expressed during
osteogenesis and their action is regulated by corresponding BMP
inhibitors. Chordin (a well recognized BMP inhibitor) and BMP-2
are expressed during osteogenic differentiation of human mesen-
chymal stem cells. Chordin inhibition induces human mesenchymal
stem cell differentiation and reduces their proliferation by increas-
ing BMP-2 bioavailability. The potential of suppressing BMP
inhibitors is emerging as a biological therapeutic target in bone
tissue engineering, because it results in an unopposed synergy
between the various growth factors that are involved in osteo-
genesis, within their physiological milieu.
Bone morphogenetic proteins (BMPs), a distinct transforming
growth factor (TGF)-β subgroup that is also involved in
organogenesis, have been shown to be expressed during
various stages of bone healing process. Mesenchymal stem
cells (MSCs) that are capable of differentiation toward the
osteogenic lineage are recruited from local deposits or the
circulation to initiate callous formation. Kwong and coworkers
[1], in their recent report, presented the expression of BMP-2
and its inhibitor chordin in human MSCs undergoing
differentiation in an osteogenic medium. Temporal and spatial
expression of BMPs, has attracted research interest because
a number of its members, namely BMP-2, -7, -9 and -14, can
induce de novo bone formation [2].
BMPs bind to two different type I and type II serine/threonine
kinase receptors. BMP heteromeric receptor complexes
activate intracellular proteins known as Smads (small ‘mothers
against’ decapentaplegic), including regulating R-Smads
(Smad1, Smad5 and Smad8), common co-Smad (Smad4),
and inhibitory I-Smads (Smad6 and Smad7), which trans-
locate to the nucleus activating specific target genes [3].
BMP inhibitors regulate local negative feedback mechanisms.
Some act extracellularly, preventing BMP binding to
receptors, whereas others act intracellularly, inhibiting Smad
downstream activation.
The most studied BMP inhibitor, noggin, reduces the activity
of both osteoblasts and osteoclasts, leading to osteopenia
and nonhealing fractures. In contrast, noggin knockout leads
to irregularly thickened long bones and is lethal shortly after
birth [4]. Chordin has a similar action to noggin. It antago-
nizes BMP-2, -4 and -7 by preventing them from activating
BMP receptors, augmented by the co-factor twisted gastru-
lation (Tsg) [5]. This causes a decrease in osteogenic differen-
tiation and a reduction in BMP-2 and BMP-4 expression
[1,5]. Gremlin, another extracellular inhibitor of BMP-2, -4 and
-7 engineered in transgenic mice, suppresses osteoblasts
with consequent osteopenia and spontaneous fractures [6].
Sclerostin, a transcription factor inhibitor, promotes apoptosis
of human MSCs and osteoblasts. Interestingly, sclerostin and
noggin - when they are expressed together - form a mutually
inhibitory complex that actually leads to promotion of BMP
activity [7]. Inhibitory Smad6 and Smad7 are found
predominantly in the cell nucleus, but they are transported
into the cell cytoplasm at times of high BMP activity. Smad6
preferentially inhibits BMP signaling, whereas Smad7 inhibits
all members of the TGF-β family [3]. Overall, BMP inhibitors
lead to downregulation of BMPs, inhibition of MSC differen-
tiation to osteoblasts, and poor fracture healing. On the other
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hand, it has been demonstrated that the lack of BMP
inhibitors in knockdown mice has an adverse effect on
development of the musculoskeletal system [1,4-7].
The report by Kwong and coworkers [1] elegantly illustrated
that a balance exists between chordin and BMP-2 expression
during human MSC differentiation into osteoblasts [1]. They
found that both chordin and BMP-2 increase during osteo-
genic differentiation of MSCs, but their effects are markedly
different. The suppression of chordin led to increased
availability of BMP-2 and subsequently differentiation of
human MSCs into osteoblasts. Those investigators further
demonstrated that suppression of chordin not only promoted
osteogenesis (differentiation) but also decreased cellular
proliferation, also mediated by BMP-2. Therefore, an inverse
relation exists between these two processes.
By inhibiting other inhibitors, some interesting recent studies
have also demonstrated in vitro and  in vivo osteogenesis.
Wan and colleagues [8] identified that accelerated bone
formation resulted from suppressing noggin expression in
both in vitro and in vivo experiments. After transfected osteo-
blasts (small-interfering RNA noggin) had been implanted into
critically sized parietal bone defects of skeletally mature mice
early (2 weeks), bone regeneration took place, with nearly
complete bony bridging by 8 weeks. Winkler and coworkers
used mouse C3H10T1/2 cells treated with rh-noggin and
transfected with bacillovirus-produced sclerostin. They
showed that combining noggin and sclerostin at a specific
concentration resulted in a single complex, neutralizing their
respective inhibitory effects. This allowed BMP signalling to
proceed to osteoinduction [7].
The multitude and complexity of BMP, TGF-β and vascular
endothelial growth factor synergy in bone regeneration is
such that the application of a single or at most two
commercially manufactured growth factors cannot be the
solution to the problem of inadequate bone healing. In
addition, high concentrations - at high cost - of single growth
factors with a range of questionable carriers is the current
paradigm for bone induction in the clinical setting [9]. The
potential of inhibiting the inhibitors is therefore of great
interest, because a single inhibitor - such as noggin or
chordin - controls several BMPs (specifically BMP-2, -4 and
-7) and therefore allows their natural synergy to regenerate
bone in a physiological state. This takes advantage of the
endogenous BMP cascade both temporally and spatially
[1,4-8]. Also, suppression of BMP inhibitors could be a
potential therapy for osteoporosis [10].
A strength of the report by Kwong and coworkers [1] is its
recognition of the role played by chordin in osteogenesis.
The authors demonstrated successful knockdown of chordin
expression by small-interfering RNA transfection of human
MSCs cultured in an osteogenic medium, and they con-
cluded that chordin suppression allows MSC differentiation
by increasing BMP-2 bioavailability. Future characterization of
all the inhibitors and technological advances in suppressing
their expression (including gene therapy, small interfering
RNA induced knockdown inhibitor expression, neutralizing
antibodies and small molecule antagonists) will allow
noninvasive ‘intelligent’ bone tissue engineering.
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